Lead sponsor
Samus Therapeutics, Inc.
2 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
2
Trials led
0
Ongoing
44
Total enrollment
11
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
1
Phase 2
1
Trials by status
Terminated
2
Trials led
TrialEligibility highlightPhaseStatusEnrollment
A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy SubjectsAge 18-75Ph 1Terminated40
To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD DementiaAlzheimer's diseasePh 2Terminated4